After 36 Years a Breakthrough for Hypothalamic Obesity

Our live talk sessions of the pituitary and adrenal podcasts continue with this extremely informational conversation on hypothalamic obesity.  If you are interested in learning more about his devastating disorder, please listen to Dr. Blevins as he shares his insights and extensive expertise on its causes, new treatments, and latest developments.   He explains the underlying biology: fat cells produce leptin, which signals the hypothalamus to regulate appetite, metabolic rate, and activity level. When the hypothalamus is damaged, that signal fails, and patients feel constantly starving, their metabolism slows, activity drops, and severe weight gain follows.

He also talks about the newly approved drug, setmelanotide (IMCIVREE), which acts like alpha-melanocyte stimulating hormone (MSH), bypassing the damaged hypothalamic pathway to suppress appetite, increase activity, and improve metabolic rate.   Clinical trial data show an average BMI reduction of 15–20%, with patients shifting into lower obesity classes and reporting meaningful improvements in quality of life and self-image.

Dr. Blevins and Dr. Galbiati have collectively written about 10 prescriptions but are waiting on insurance approvals.  He notes that long-term data beyond 52 weeks is still needed, and that real-world outcomes will be the true test of the drug’s lasting impact. Read the recent PWN article on FDA’s Approval of IMCIVREE® for Acquired Hypothalamic Obesity.  Dr. Blevins and Dr. Galbiati will report and share the information on a podcast once the clinic’s information is available.   Stay tuned for that.